Unintended benefits: The potential economic impact of addressing risk factors to prevent Alzheimer's disease

Health Affairs

Volumn 33, Issue 4, 2014, Pages 547-554

  Lin, Pei Jung ^a,b   Yang, Zhou ^c   Fillit, Howard M ^d,e,f   Cohen, Joshua T ^b,g   Neumann, Peter J ^b,g  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c EMORY UNIVERSITY   (United States)

^d Alzheimer's Drug Discovery Foundation   (United States)

^e MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^f ROCKEFELLER UNIVERSITY   (United States)

^g Center for the Evaluation of Value and Risk in Health   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; ARTICLE; BODY MASS; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; HEALTH ECONOMICS; HYPERTENSION; MEDICARE; RISK FACTOR;

EID: 84898022333     PISSN: 02782715     EISSN: 15445208     Source Type: Journal    
DOI: 10.1377/hlthaff.2013.1276     Document Type: Article

References (49)

1. Cutler DM, Rosen AB, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med. 2006;355(9):920-7.
2. Hoyert DL, Xu J. Deaths: preliminary data for 2011. Natl Vital Stat Rep. 2012;61(6).
3. Bassil N, Grossberg GT. Evidencebased approaches to preventing Alzheimer's disease, part 1. Prim Psychiatry. 2009;16(6):29-37.
4. Exalto LG, Biessels GJ, Karter AJ, Huang ES, Katon WJ, Minkoff JR, et al. Risk score for prediction of 10 year dementia risk in individuals with type 2 diabetes: a cohort study. Lancet Diabetes Endocrinol. 2013; 1(3):183-90.
5. Gauthier S,Wu L, Rosa-Neto P, Jia J. Prevention strategies for Alzheimer's disease. Transl Neurodegener. 2012;1(1):13.
6. Kivipelto M, Ngandu T, Laatikainen T, Winblad B, Soininen H, Tuomilehto J. Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurol. 2006;5(9): 735-41.
7. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505-12.
8. Daviglus ML, Bell CC, Berrettini W, Bowen PE, Connolly ES Jr, Cox NJ, et al. NIH state-of-the-science conference statement: preventing Alzheimer's disease and cognitive decline. NIH Consens State Sci Statements. 2010;27(4):1-30.
9. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64-74.
10. Ciobica A, Padurariu M, Bild W, Stefanescu C. Cardiovascular risk factors as potential markers for mild cognitive impairment and Alzheimer's disease. Psychiatr Danub. 2011;23(4):340-6.
11. Roberts RO, Knopman DS, Geda YE, Cha RH, Pankratz VS, Baertlein L, et al. Association of diabetes with amnestic and nonamnestic mild cognitive impairment. Alzheimers Dement. 2014;10(1):18-26.
12. Yang Y, Song W. Molecular links between Alzheimer's disease and diabetes mellitus. Neuroscience. 2013;250:140-50.
13. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 2011;10(9):819-28.
14. Gifford KA, Badaracco M, Liu D, Tripodis Y, Gentile A, Lu Z, et al. Blood pressure and cognition among older adults: a meta-analysis. Arch Clin Neuropsychol. 2013;28(7): 649-64.
15. Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors. Curr Alzheimer Res. 2013;10(8):852-67.
16. Forette F, Seux ML, Staessen JA, Thijs L, Babarskiene MR, Babeanu S, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med. 2002; 162(18):2046-52.
17. Peters R, Beckett N, Forette F, Tuomilehto J, Clarke R, Ritchie C, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVETCOG): a double-blind, placebo controlled trial. Lancet Neurol. 2008;7(8):683-9.
18. Cramer C, Haan MN, Galea S, Langa KM, Kalbfleisch JD. Use of statins and incidence of dementia and cognitive impairment without dementia in a cohort study. Neurology. 2008; 71(5):344-50.
19. Sparks DL, Kryscio RJ, Sabbagh MN, Connor DJ, Sparks LM, Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr Alzheimer Res. 2008; 5(4):416-21.
20. Wolozin B, Wang SW, Li N-C, Lee A, Lee TA, Kazis LE. Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med. 2007;5:20.
21. Yasar S, Xia J, Yao W, Furberg CD, Xue QL, Mercado CI, et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896-903.
22. Goldman DP, Cutler D, Rowe JW, Michaud P-C, Sullivan J, Peneva D, et al. Substantial health and economic returns from delayed aging may warrant a new focus for medical research. Health Aff (Millwood). 2013;32(10):1698-705.
23. Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM. Monetary costs of dementia in the United States. N Engl J Med. 2013;368(14): 1326-34.
24. Lin PJ, Kaufer DI, Maciejewski ML, Ganguly R, Paul JE, Biddle AK. An examination of Alzheimer's disease case definitions using Medicare claims and survey data. Alzheimers Dement. 2010;6(4):334-41.
25. To access the Appendix, click on the Appendix link in the box to the right of the article online.
26. Yang Z, Hall AG. The financial burden of overweight and obesity among elderly Americans: the dynamics of weight, longevity, and health care cost. Health Serv Res. 2008;43(3):849-68.
27. Yang Z, Zhang K, Lin PJ, Clevenger C, Atherly A. A longitudinal analysis of the lifetime cost of dementia. Health Serv Res. 2012;47(4): 1660-78.
28. Lakdawalla DN, Goldman DP, Shang B. The health and cost consequences of obesity among the future elderly. Health Aff (Millwood). 2005;24: w5-r30-41. DOI: 10.1377/hlthaff.w5 .r30.
29. Lin PJ, Fillit HM, Cohen JT, Neumann PJ. Potentially avoidable hospitalizations among Medicare beneficiaries with Alzheimer's disease and related disorders. Alzheimers Dement. 2013;9(1):30-8.
30. Plassman BL, Langa KM, Fisher GG, Heeringa SG,Weir DR, Ofstedal MB, et al. Prevalence of dementia in the United States: the aging, demographics, and memory study. Neuroepidemiology. 2007;29(1-2): 125-32.
31. Areosa SA, Grimley EV. Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia. Cochrane Database Syst Rev. 2002(4): CD003804.
32. Lu FP, Lin KP, Kuo HK. Diabetes and the risk of multi-system aging phenotypes: a systematic review and meta-analysis. PloS One. 2009;4(1): e4144.
33. Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology. 2005;64(2):277-81.
34. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6): 393-403.
35. Taylor DH Jr, Østbye T, Langa KM, Weir D, Plassman BL. The accuracy of Medicare claims as an epidemiological tool: the case of dementia revisited. J Alzheimers Dis. 2009; 17(4):807-15.
36. Maruszak A, Safranow K, Branicki W, Gaweda-Walerych K, Pospiech E, Gabryelewicz T, et al. The impact of mitochondrial and nuclear DNA variants on late-onset Alzheimer's disease risk. J Alzheimers Dis. 2011;27(1):197-210.
37. Yang Z, Lin PJ, Levey A. Monetary costs of dementia in the United States. N Engl J Med. 2013; 369(5):489.
38. Carrillo MC, Brashear HR, Logovinsky V, Ryan JM, Feldman HH, Siemers ER, et al. Can we prevent Alzheimer's disease? Secondary "prevention" trials in Alzheimer's disease. Alzheimers Dement. 2013; 9(2):123-31.
39. Thal LJ. Prevention of Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20(3 Suppl 2):S97-9.
40. Stampfer MJ. Cardiovascular disease and Alzheimer's disease: common links. J Intern Med. 2006;260(3): 211-23.
41. Goldman DP, Zheng Y, Girosi F, Michaud PC, Olshansky SJ, Cutler D, et al. The benefits of risk factor prevention in Americans aged 51 years and older. Am J Public Health. 2009;99(11):2096-101.
42. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Circulation. 2008; 118(5):576-85.
43. Maciosek MV, Coffield AB, Flottemesch TJ, Edwards NM, Solberg LI. Greater use of preventive services in U.S. health care could save lives at little or no cost. Health Aff (Millwood). 2010;29(9): 1656-60.
44. National Business Group on Health. A purchaser's guide to clinical preventive services: moving science into coverage. Washington (DC): NBGH; 2007.
45. National Heart, Lung, and Blood Institute. Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults: the evidence report [Internet]. Bethesda (MD): National Institutes of Health; 1998 Sep [cited 2014 Mar 3]. (NIH Publication No. 98-4083). Available from: http://www.nhlbi.nih.gov/guide lines/obesity/ob_gdlns.pdf
46. Stevens VJ, Obarzanek E, Cook NR, Lee IM, Appel LJ, SmithWest D, et al. Long-term weight loss and changes in blood pressure: results of the Trials of Hypertension Prevention, phase II. Ann Intern Med. 2001; 134(1):1-11.
47. Forette F, Seux ML, Staessen JA, Thijs L, Birkenhäger WH, Babarskiene MR, et al. Prevention of dementia in randomised doubleblind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137): 1347-51.
48. Fries JF. The compression of morbidity. Milbank Q. 2005;83(4): 801-23.
49. How to cope with an ageing population. Lancet. 2013;382(9900): 1225.